MAIA icon

MAIA Biotechnology

2.02 USD
-0.02
0.98%
At close Dec 20, 4:00 PM EST
After hours
1.96
-0.06
2.97%
1 day
-0.98%
5 days
-8.18%
1 month
-9.42%
3 months
-30.10%
6 months
-41.11%
Year to date
69.75%
1 year
100.00%
5 years
-54.71%
10 years
-54.71%
 

About: MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.

Employees: 13

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

2.07% less ownership

Funds ownership: 8.21% [Q2] → 6.14% (-2.07%) [Q3]

19% less funds holding

Funds holding: 21 [Q2] → 17 (-4) [Q3]

32% less capital invested

Capital invested by funds: $6.11M [Q2] → $4.15M (-$1.96M) [Q3]

57% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 7

Research analyst outlook

We haven’t received any recent analyst ratings for MAIA.

Financial journalist opinion

Based on 4 articles about MAIA published over the past 30 days

Neutral
Business Wire
3 days ago
MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings.
MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings
Neutral
Business Wire
6 days ago
MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas.
MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas
Neutral
Business Wire
1 week ago
MAIA Biotechnology Announces Private Placement of Approximately $950,000
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Private Placement of Approximately $950,000.
MAIA Biotechnology Announces Private Placement of Approximately $950,000
Neutral
Business Wire
2 weeks ago
MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer.
MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer
Neutral
Business Wire
1 month ago
MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement.
MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement
Neutral
Business Wire
1 month ago
MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the SITC 39th Annual Meeting.
MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Neutral
Business Wire
1 month ago
MAIA Biotechnology Announces $2.44 Million Private Placement
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces $2.44 Million Private Placement.
MAIA Biotechnology Announces $2.44 Million Private Placement
Neutral
Business Wire
2 months ago
MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics.
MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics
Neutral
Business Wire
3 months ago
MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference.
MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference
Positive
Benzinga
5 months ago
MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients
On Tuesday, MAIA Biotechnology Inc MAIA announced treatment updates from its Phase 2 THIO-101 trial of THIO sequenced with Regeneron Pharmaceuticals Inc's REGN cemiplimab (Libtayo) for advanced non-small-cell-lung-cancer patients who failed two or more standard-of-care therapy regimens.
MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients
Charts implemented using Lightweight Charts™